Legend Biotech (LEGN) Stock Price Target Raised by UBS on NHL Outlook
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowUBS increased its price target for Legend Biotech (LEGN) reflecting a positive outlook on its NHL therapy development. No specific new price target was provided in the report. The adjustment signifies UBS's confidence in the market potential of LEGN's therapeutic advancements and could influence investor sentiment positively. This change might impact trading volumes as investors react to the report, indicating potential shifts in the stock's market dynamics.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
